Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chitra Venkatasubramanian

Vascular Neurology Stanford, CA Medical Doctor

NPI 1912930678 CMS profile 86220

300 Pasteur Dr, Stanford, CA 94305

Open in the dashboard

General payments

$260,059

168 records reported · program years 2019–2025

Research payments

$10,125

Paid to them · 9 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$587,347 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Chitra Venkatasubramanian of Stanford, CA is reported in the CMS Open Payments database as having received $260,059 across 168 general payments and $10,125 in research payments paid to them. Separately, studies naming them as principal investigator received $587,347 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Vascular Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $61,506 26
2025 Research $10,125 9
2024 General $88,731 43
2023 General $31,933 23
2022 General $25,902 33
2021 General $17,325 17
2020 General $23,869 7
2019 General $10,793 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chitra Venkatasubramanian
  • Vascular Neurology median
  • Middle half of Vascular Neurology
  • National median

In program year 2025, general payments to Chitra Venkatasubramanian were reported at $61,506. Among 416 Vascular Neurology profiles paid that year, the median was $360 and the middle half received between $91 and $1,472.

Show as a table
Year Chitra Venkatasubramanian Vascular Neurology median Middle half National median
2019 $10,793 $263 $102–$1,640 $163
2020 $23,869 $153 $45–$1,000 $114
2021 $17,325 $261 $100–$1,355 $132
2022 $25,902 $242 $87–$1,273 $149
2023 $31,933 $322 $97–$1,266 $160
2024 $88,731 $247 $70–$1,053 $164
2025 $61,506 $360 $91–$1,472 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ceribell, Inc. $129,097 32 payments
  2. AbbVie, Inc. $110,730 89 payments
  3. Portola Pharmaceuticals, Inc. $7,600 1 payment
  4. AstraZeneca Pharmaceuticals LP $6,413 10 payments
  5. Alnylam Pharmaceuticals Inc. $3,182 14 payments
  6. Biogen, Inc. $2,418 15 payments
  7. UCB, Inc. $343 3 payments
  8. United Therapeutics Corporation $116 2 payments
  9. Hyperfine Operations, Inc. $102 1 payment
  10. Medivance, Inc. $57 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $239,876 99 payments
  2. Travel and Lodging $10,071 26 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,600 1 payment
  4. Food and Beverage $2,485 41 payments
  5. Education $27 1 payment
Products named General payments · program years 2019–2025
  1. POCKET EEG DEVICE $127,427 29 payments
  2. RINVOQ $30,488 25 payments
  3. SKYRIZI Immunology $20,800 11 payments
  4. ANDEXXA Hematology/Neurology $7,600 1 payment
  5. ANDEXXA Rare Disease $3,114 6 payments
  6. Ceribell Rapid Response EEG $1,646 2 payments
  7. SKYRIZI Immunology $1,300 3 payments
  8. Briviact $343 3 payments
  9. TYVASO $116 2 payments
  10. Swoop $102 1 payment
  11. Other $57 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $10,125 9 payments

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$56,581

Medicare's payments for the services billed

Medicare patients

143

Average age 74

Services billed

342

66 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 45%
Ischemic heart disease 45%
Atrial fibrillation 41%
Chronic kidney disease 41%
Arthritis 34%
Heart failure 33%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $7,150
$7,150 — —
RINVOQ
  • AbbVie, Inc. $5,850
$5,850 — —
Briviact
  • UCB, Inc. $196
$196 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record